COR2ED The Heart of Medical Education
Our COR2ED channel brings together world-renowned medical experts to discuss and provide clear guidance on the latest scientific and clinical insights in various therapeutic areas, including oncology, cardiology, hemostasis, rare diseases, hemato-oncology, and endocrinology. At COR2ED, we are committed to providing balanced and evidence-based independent medical education to support healthcare ...
read more ↘
read more ↘
ASCO® 2024 Summary: "The Latest Data in Oncogene-Addicted NSCLC"
By
COR2ED The Heart of Medical Education
FEATURING
Nicolas Girard
By
COR2ED The Heart of Medical Education
FEATURING
Nicolas Girard
In this conference highlights video, Prof. Nicolas Girard shares his perspective on the latest data in oncogene-addicted non-small cell lung cancer (NSCLC) from ASCO 2024.
Prof. Girard reviews data from the following clinical trials:
- PALOMA-2 and PALOMA-3
- CROWN
- KRYSTAL-12
- SOHO-01
- Beamion LUNG-1
Download the accompanying slides from the COR2ED website.
Clinical Takeaways
EGFR:
- PALOMA-2: provides evidence for the efficacy and safety of subcutaneous amivantamab + lazertinib and suggests it could be suitable as a first-line option for patients with EGFR-mutant advanced NSCLC
- PALOMA-3:subcutaneous amivantamab with lazertinib is noninferior to intravenous amivantamab plus lazertinib and has an improved safety profile and greater convenience
ALK:
- CROWN:after 5 years of treatment, the median PFS of patients with advanced ALK-positive NSCLC treated with lorlatinib has yet to be reached, corresponding with the longest PFS ever reported in advanced NSCLC
KRAS:
- KRYSTAL-12: adagrasib demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR over docetaxel in patients with previously treated KRASG12C-mutated NSCLC
HER2:
- SOHO-01: in patients with heavily pre-treated HER2-mutant NSCLC, treatment with BAY 2927088 resulted in rapid, substantial and durable responses
- Beamion LUNG-1: zongertinib was well tolerated and demonstrated promising initial efficacy in pre-treated patients with HER2-mutated NSCLC
Follow LUNG CONNECT on:
X
LinkedIn
This content is intended for healthcare professionals only. Published June 2024.
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Medical Education Grant from Bayer.
This video is developed by cor2ed.com
Prof. Girard reviews data from the following clinical trials:
- PALOMA-2 and PALOMA-3
- CROWN
- KRYSTAL-12
- SOHO-01
- Beamion LUNG-1
Download the accompanying slides from the COR2ED website.
Clinical Takeaways
EGFR:
- PALOMA-2: provides evidence for the efficacy and safety of subcutaneous amivantamab + lazertinib and suggests it could be suitable as a first-line option for patients with EGFR-mutant advanced NSCLC
- PALOMA-3:subcutaneous amivantamab with lazertinib is noninferior to intravenous amivantamab plus lazertinib and has an improved safety profile and greater convenience
ALK:
- CROWN:after 5 years of treatment, the median PFS of patients with advanced ALK-positive NSCLC treated with lorlatinib has yet to be reached, corresponding with the longest PFS ever reported in advanced NSCLC
KRAS:
- KRYSTAL-12: adagrasib demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR over docetaxel in patients with previously treated KRASG12C-mutated NSCLC
HER2:
- SOHO-01: in patients with heavily pre-treated HER2-mutant NSCLC, treatment with BAY 2927088 resulted in rapid, substantial and durable responses
- Beamion LUNG-1: zongertinib was well tolerated and demonstrated promising initial efficacy in pre-treated patients with HER2-mutated NSCLC
Follow LUNG CONNECT on:
X
This content is intended for healthcare professionals only. Published June 2024.
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Medical Education Grant from Bayer.
This video is developed by cor2ed.com
Comments 0
Login to view comments.
Click here to Login
